StemCell Therapy

Arcturus Therapeutics Holdings Inc (ARCT) is near the top in its industry group according to InvestorsObserver. ARCT gets an overall rating of 66. That means it scores higher than 66 percent of stocks. Arcturus Therapeutics Holdings Inc gets a 82 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Arcturus Therapeutics Holdings Inc (ARCT) stock is trading at $53.50 as of 11:40 AM on Thursday, Oct 8, an increase of $2.58, or 5.07% from the previous closing price of $50.92. The stock has traded between $51.70 and $55.13 so far today. Volume today is low. So far 331,678 shares have traded compared to average volume of 713,777 shares.

Click Here to get the full Stock Score Report on Arcturus Therapeutics Holdings Inc (ARCT) Stock.

Go here to read the rest:
Is Arcturus Therapeutics Holdings Inc (ARCT) the Top Pick in the Biotechnology Industry? - InvestorsObserver

This entry was posted on October 8, 2020 at 10:52 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |